Cite
HARVARD Citation
Glatt, S. et al. (n.d.). First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. British journal of clinical pharmacology. pp. 991-1001. [Online].